Proteomics International Laboratories’ PromarkerD test paving the way for early detection of diabetic kidney disease
Proteomics International Laboratories (ASX: PIQ) has obtained what it describes as “groundbreaking” results in its development of treatments for deadly type 1 diabetes.
More than 130,000 Australians live with type 1 diabetes, which currently accounts for around 10% of the nation’s diabetes cases and cannot be prevented.
Globally, diabetes has emerged as the largest single cause of end-stage renal disease in developed and developing countries, affecting over half a billion people worldwide.
PromarkerD success
The success of the company’s candidate PromarkerD in predicting renal decline in type 1 diabetes will be presented today at the Australasian Diabetes Conference in Perth, Western Australia.
Delegates attending the session will hear how Proteomics’ Fremantle Diabetes Phase II study found that researchers using the PromarkerD test were able to assess its efficacy in a cohort of 92 individuals with type 1 diabetes.
The findings have also been accepted for publication in the Journal of Clinical Diabetes and Endocrinology.
Kidney health
“This significant advancement highlights the versatility and robustness of the PromarkerD test,” managing director Dr Richard Lipscombe said.
“We are excited about the potential impact this could have on managing kidney health in both type 1 and type 2 diabetes patients.”
He added that Proteomics is aiming to fill a significant gap in the medical field with PromarkerD by focusing on the lack of prognostic biomarkers for chronic kidney disease in individuals with type 1 diabetes.
Results to date are promising, with PromarkerD confirming previous validation of accurately predicting the onset of diabetic kidney disease and future kidney function decline in patients with type 2 diabetes up to four years in advance.
Early detection
Consultant physician and endocrinologist at Fremantle Hospital and Professor of Medicine at the University of Western Australia Tim Davis, the lead author of the study, said the early detection capabilities of PromarkerD are particularly beneficial for type 1 diabetes patients due to their unique clinical needs.
“By identifying at-risk individuals years before traditional methods, we can intervene sooner, potentially preventing significant renal complications and improving overall patient outcomes,” he said.
Dr Lipscombe says the preliminary findings suggest that the PromarkerD test is heralding a new era in diabetic kidney disease management.